SG10201601224WA - Interrogatory cell-based assays and uses thereof - Google Patents

Interrogatory cell-based assays and uses thereof

Info

Publication number
SG10201601224WA
SG10201601224WA SG10201601224WA SG10201601224WA SG10201601224WA SG 10201601224W A SG10201601224W A SG 10201601224WA SG 10201601224W A SG10201601224W A SG 10201601224WA SG 10201601224W A SG10201601224W A SG 10201601224WA SG 10201601224W A SG10201601224W A SG 10201601224WA
Authority
SG
Singapore
Prior art keywords
based assays
interrogatory
cell
interrogatory cell
assays
Prior art date
Application number
SG10201601224WA
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG10201601224WA publication Critical patent/SG10201601224WA/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20Probabilistic models
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
SG10201601224WA 2011-03-02 2012-03-02 Interrogatory cell-based assays and uses thereof SG10201601224WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448587P 2011-03-02 2011-03-02
US201261593848P 2012-02-01 2012-02-01

Publications (1)

Publication Number Publication Date
SG10201601224WA true SG10201601224WA (en) 2016-03-30

Family

ID=46758320

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601224WA SG10201601224WA (en) 2011-03-02 2012-03-02 Interrogatory cell-based assays and uses thereof
SG2013065529A SG193006A1 (en) 2011-03-02 2012-03-02 Interrogatory cell-based assays and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013065529A SG193006A1 (en) 2011-03-02 2012-03-02 Interrogatory cell-based assays and uses thereof

Country Status (20)

Country Link
US (3) US9886545B2 (en)
EP (1) EP2680925B1 (en)
JP (2) JP6105491B2 (en)
KR (1) KR102071081B1 (en)
CN (2) CN103501859B (en)
AU (2) AU2012223136B2 (en)
BR (1) BR112013022208A2 (en)
CA (1) CA2828972C (en)
CL (2) CL2013002526A1 (en)
CO (1) CO6801640A2 (en)
EA (1) EA201391245A1 (en)
ES (1) ES2777894T3 (en)
IL (2) IL228096B (en)
MX (1) MX358408B (en)
MY (2) MY181093A (en)
PE (2) PE20180776A1 (en)
PH (2) PH12017502073A1 (en)
SG (2) SG10201601224WA (en)
WO (1) WO2012119129A1 (en)
ZA (1) ZA201306453B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004273783A1 (en) 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
ES2551922T3 (en) 2011-03-07 2015-11-24 Accelerate Diagnostics, Inc. Rapid cell purification systems
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
JP2015517801A (en) * 2012-03-05 2015-06-25 バーグ エルエルシー Compositions and methods for diagnosis and treatment of pervasive developmental disorders
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EP2834366A4 (en) 2012-04-02 2016-04-27 Berg Llc Interrogatory cell-based assays and uses thereof
AU2012381038B2 (en) 2012-05-22 2019-03-07 Berg Llc Interrogatory cell-based assays for identifying drug-induced toxicity markers
US20150302140A1 (en) * 2012-11-02 2015-10-22 H. Lee Moffit Cancer Center And Research Institute, Inc. In silico identification of cancer molecular signaling pathways and drug candidates
US20150302167A1 (en) * 2012-11-09 2015-10-22 Cellworks Group, Inc. System and method for development of therapeutic solutions
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
JP6216044B2 (en) * 2013-05-28 2017-10-18 ファイヴ3 ゲノミクス,エルエルシー PARADIGM drug reaction network
EP3017300A4 (en) * 2013-07-01 2017-03-08 Ixcela, Inc. Systems biology approach to therapy
KR20170028322A (en) * 2014-05-28 2017-03-13 비토 엔브이 A method for the relative quantification of chemical compounds contained in a mixture of different biological samples
JP6916107B2 (en) 2014-09-11 2021-08-11 バーグ エルエルシー Bayesian Causal Network Model for Health Examination and Treatment Based on Patient Data
SG11201702490PA (en) * 2014-10-10 2017-04-27 Akira Matsumori Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
KR20170132856A (en) 2015-03-30 2017-12-04 액셀러레이트 다이어그노스틱스, 아이엔씨. Instruments and systems for rapid microbiological identification and antimicrobial susceptibility testing
CN106250717B (en) * 2015-06-04 2019-03-12 徐勇 The miRNA of acute myeloid leukaemia and the system of transcription factor and its construction method and application
KR101881398B1 (en) * 2016-04-07 2018-07-24 한국과학기술원 Apparatus and method for processing biological system information
WO2017214068A1 (en) 2016-06-05 2017-12-14 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
US10282588B2 (en) * 2016-06-09 2019-05-07 Siemens Healthcare Gmbh Image-based tumor phenotyping with machine learning from synthetic data
EP3538095A4 (en) 2016-11-14 2020-06-17 Berg LLC Methods for treating parkinson's disease
WO2018094204A1 (en) * 2016-11-17 2018-05-24 Arivale, Inc. Determining relationships between risks for biological conditions and dynamic analytes
CN110892080A (en) * 2017-05-12 2020-03-17 美国控股实验室公司 Compositions and methods for detecting diseases associated with exposure to inhaled carcinogens
EP3814944A4 (en) * 2018-06-29 2022-04-06 The Jackson Laboratory Methods and apparatus for identifying alternative splicing events
CN109086570B (en) * 2018-06-29 2020-09-04 迈凯基因科技有限公司 Multi-database sequential interaction method and device
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
JP2022523564A (en) 2019-03-04 2022-04-25 アイオーカレンツ, インコーポレイテッド Data compression and communication using machine learning
US20220246231A1 (en) * 2019-07-09 2022-08-04 Shimadzu Corporation Method for constructing model for predicting differentiation efficiency of ips cell and method for predicting differentiation efficiency of ips cell
US20210071256A1 (en) * 2019-09-11 2021-03-11 Recursion Pharmaceuticals, Inc. Systems and methods for pairwise inference of drug-gene interaction networks
CN112151109B (en) * 2020-09-09 2023-08-25 中国科学院大连化学物理研究所 Semi-supervised learning method for evaluating randomness of biomolecule cross-linked mass spectrometry identification
CN112466403B (en) * 2020-12-31 2022-06-14 广州基迪奥生物科技有限公司 Cell communication analysis method and system
KR102556312B1 (en) 2021-04-12 2023-07-19 서울대학교병원 Kidney-mimicking organ chip comprising tubular culture section and interstitial culture section
WO2023102204A1 (en) * 2021-12-03 2023-06-08 The Trustees Of Indiana University Biomarker for type 1 diabetes
CN116046877B (en) * 2023-04-03 2024-03-15 深圳先进技术研究院 Metabolic analysis method for disease model, embedding mould and spraying device

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
DE69233331T3 (en) 1991-11-22 2007-08-30 Affymetrix, Inc., Santa Clara Combinatorial Polymersynthesis Strategies
CA2087413A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Fluorescent energy transfer immunoassay
US5918200A (en) * 1992-08-31 1999-06-29 Yamatake-Honeywell Co., Ltd. State estimating apparatus
WO1994016101A2 (en) 1993-01-07 1994-07-21 Koester Hubert Dna sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
AU687801B2 (en) 1993-03-19 1998-03-05 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
EP1027456B1 (en) 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2324995A1 (en) * 1998-04-17 1999-10-28 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
CA2441060A1 (en) 2001-03-13 2002-09-19 Ashni Naturaceuticals, Inc. Method for association of genomic and proteomic pathways associated with physiological or pathophysiological processes
US8000949B2 (en) 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004021144A2 (en) 2002-08-29 2004-03-11 Gene Network Sciences, Inc. Systems and methods for inferring biological networks
CN1714371A (en) * 2002-11-19 2005-12-28 Gni美国公司 Nonlinear modeling of gene networks from time series gene expression data
JP4288345B2 (en) 2003-06-19 2009-07-01 独立行政法人産業技術総合研究所 New epilepsy model animal
EP1512970A1 (en) 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for determining the impact of a multicomponent mixture on the biological profile of a disease
US20070134734A1 (en) 2003-10-14 2007-06-14 Cellfree Sciences Co., Ltd. Novel screening method of indicator substance
WO2005107412A2 (en) * 2004-04-30 2005-11-17 Rosetta Inpharmatics Llc Systems and methods for reconstruction gene networks in segregating populations
EP1607898A3 (en) 2004-05-18 2006-03-29 Neal E. Solomon A bioinformatics system for functional proteomics modelling
US20100316629A1 (en) 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
AU2006206159A1 (en) 2005-01-24 2006-07-27 Massachusetts Institute Of Technology Method for modeling cell signaling systems by means of bayesian networks
JP2008537821A (en) 2005-03-31 2008-09-25 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ System and method for collecting evidence regarding the relationship between biomolecules and diseases
EP1887351A4 (en) 2005-05-31 2009-04-08 Jcl Bioassay Corp Screening method for specific protein in proteome comprehensive analysis
CA2622852A1 (en) 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
JPWO2007086515A1 (en) * 2006-01-27 2009-06-25 武田薬品工業株式会社 Gene expression analysis tool
US8571803B2 (en) * 2006-11-15 2013-10-29 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
CN101105841B (en) * 2007-02-12 2011-06-15 浙江大学 Method for constructing gene controlled subnetwork by large scale gene chip expression profile data
US8140270B2 (en) * 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
WO2009020684A1 (en) 2007-05-16 2009-02-12 Edsa Micro Corporation Real-time predictive systems for intelligent energy monitoring and management of electrical power networks
JP2009050171A (en) 2007-08-23 2009-03-12 Toyobo Co Ltd Method for detecting phosphorylation on substrate by surface plasmon resonance
US7895146B2 (en) * 2007-12-03 2011-02-22 Microsoft Corporation Time modulated generative probabilistic models for automated causal discovery that monitors times of packets
US20110071049A1 (en) * 2008-03-12 2011-03-24 Nathaniel Heintz Methods and compositions for translational profiling and molecular phenotyping
KR20110044905A (en) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. Methods and systems for predicting cell response to therapeutic agents
AU2010247750B2 (en) 2009-05-11 2016-09-22 Berg Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP2600154A4 (en) 2010-03-31 2014-06-11 Univ Kumamoto Nat Univ Corp Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same
EP2834366A4 (en) 2012-04-02 2016-04-27 Berg Llc Interrogatory cell-based assays and uses thereof
EP3017300A4 (en) * 2013-07-01 2017-03-08 Ixcela, Inc. Systems biology approach to therapy

Also Published As

Publication number Publication date
AU2012223136A1 (en) 2013-09-19
CA2828972A1 (en) 2012-09-07
MX358408B (en) 2018-08-20
US9886545B2 (en) 2018-02-06
PH12017502073A1 (en) 2019-01-14
CL2013002526A1 (en) 2014-04-25
CL2020002805A1 (en) 2021-04-30
MY181093A (en) 2020-12-17
US20180260515A1 (en) 2018-09-13
EP2680925A1 (en) 2014-01-08
CN107273712A (en) 2017-10-20
US11456054B2 (en) 2022-09-27
ES2777894T3 (en) 2020-08-06
NZ712105A (en) 2017-05-26
EP2680925B1 (en) 2019-11-20
ZA201306453B (en) 2021-05-26
JP6105491B2 (en) 2017-03-29
US20240062844A1 (en) 2024-02-22
NZ614891A (en) 2016-01-29
PE20180776A1 (en) 2018-05-07
PE20140627A1 (en) 2014-05-30
EA201391245A1 (en) 2014-05-30
CN107273712B (en) 2021-12-03
KR20140013006A (en) 2014-02-04
AU2017202977A1 (en) 2017-05-25
JP2014512520A (en) 2014-05-22
PH12017502072A1 (en) 2019-01-14
MX2013010068A (en) 2013-11-01
AU2017202977B2 (en) 2019-09-19
IL257824A (en) 2018-04-30
CO6801640A2 (en) 2013-11-29
BR112013022208A2 (en) 2022-03-08
CN103501859A (en) 2014-01-08
MY164530A (en) 2017-12-29
WO2012119129A1 (en) 2012-09-07
EP2680925A4 (en) 2014-12-31
KR102071081B1 (en) 2020-01-29
IL228096A0 (en) 2013-09-30
IL228096B (en) 2018-03-29
US20120258874A1 (en) 2012-10-11
AU2012223136B2 (en) 2017-05-25
JP2017148046A (en) 2017-08-31
CA2828972C (en) 2021-09-07
CN103501859B (en) 2017-08-25
SG193006A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
IL257824A (en) Interrogatory cell-based assays and uses thereof
HK1209161A1 (en) Interrogatory cell-based assays and uses thereof
HUS2100034I1 (en) Anti-angptl3 antibodies and uses thereof
IL288203B (en) Meditopes and meditope-binding antibodies and uses thereof
HK1251033A1 (en) Whole cell assays and methods
IL232399A0 (en) Anti-fgfr2 antibodies and uses thereof
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
IL229315B (en) Chaperone interaction assays and uses thereof
EP2744891A4 (en) Neurogenic and gliogenic factors and assays therefor
GB201220662D0 (en) Assays
EP2627788A4 (en) Microvesicle-based assays
GB201212550D0 (en) B cell assay
GB201014688D0 (en) Environmental seating sign
GB201209980D0 (en) Biochemical assays
GB201117881D0 (en) Biomarkers and uses thereof
GB201114341D0 (en) Reagent and use
GB201116030D0 (en) Enzyme assays
GB201110920D0 (en) Enzyme assays
GB201105118D0 (en) Enzyme assays